Brief: Moberg Pharma Meets Primary Endpoint For MOB-015 In Phase 3 Study For Treatment Of Onychomycosis

Moberg Pharma AB (publ)

09/12/2019 07:04

Dec 9 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA MEETS PRIMARY ENDPOINT FOR MOB-015 IN A
PHASE 3
STUDY FOR THE TREATMENT OF ONYCHOMYCOSIS
    * MOB-015 (TOPICAL TERBINAFINE) MET PRIMARY ENDPOINT AS WELL
AS
KEY SECONDARY ENDPOINTS IN NORTH AMERICAN PHASE 3 STUDY
INCLUDING 365 PATIENTS WITH MILD TO MODERATE TOENAIL
ONYCHOMYCOSIS (NAIL FUNGUS)
    * AT WEEK 52, SIGNIFICANTLY MORE PATIENTS REACHED COMPLETE
CURE
FOR MOB-015 THAN FOR VEHICLE (P=0.019), FOLLOWING 48 WEEKS OF
DAILY TREATMENT
    * PRIMARY ENDPOINT, PROPORTION OF PATIENTS ACHIEVING
COMPLETE CURE
OF THEIR TARGET TOENAIL AT 52 WEEKS, WAS ACHIEVED IN 4.5 PERCENT
OF PATIENTS FOR MOB-015 AND IN NONE OF PATIENTS RECEIVING
VEHICLE (P=0.019)
    * MOB-015 WAS GENERALLY WELL TOLERATED
    * NO SAFETY ISSUES WERE IDENTIFIED IN TRIAL AND NO SERIOUS
ADVERSE
EVENTS RELATED TO MOB-015 WERE REPORTED

Source text for Eikon:  ID:nWkr84Wx39 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))